Medical professionals use the term “compassionate use” to refer to the treatment of a patient using a new, unapproved drug when no other treatments are available. Drugs that are being tested but have not yet been approved by the US Food and Drug Administration (FDA) are called investigational drugs. These drugs are generally available only to people who are taking part in a clinical trial. Being able to use one of these drugs when you are not in a clinical trial is most commonly referred to as compassionate use (American Cancer Society®).
“There is nothing more difficult than having to look at parents in the eye and tell them, ‘I'm sorry, there is nothing more we can do,’" said Dr. Guillermo De Angulo, Pediatric Oncologist in Miami. "The promise of a potential new treatment option for compassionate use in children is very promising and very much needed.”
In September 2016, The Live Like Bella® Childhood Cancer Foundation announced their partnership with Biomarck Pharmaceuticals and their plan to offer BIO-11006 for compassionate use starting the spring of 2017 for children battling certain types of cancer. It is amazing news that the FDA has allowed for human trails to begin and that Biomarck is moving forward to offer BIO-11006 for compassionate use.
Biomarck Pharmaceuticals, Inc. is a North Carolina biopharma company focused on developing products for serious diseases such as lung cancer and acute respiratory distress syndrome (ARDS). In conjunction with North Carolina State University and Live Like Bella® Foundation, Biomarck is delighted to support a compassionate use program in children with cancers who are not responding to approved therapy. For more information visit www.biomarck.com.
For more information on compassionate use of this investigational drug, please contact your physician and have them email us at email@example.com
Please click on the link below for important information regarding compassionate use of BIO-11006.